For the second time in two months, Celcuity Inc. failed to generate investor excitement despite disclosing positive news, this time following the U.S. FDA approval of...

Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even though...

After decades of clinical research and false starts, have Brain-Computer Interface (BCI) systems finally arrived? Read BioWorld's special series.

Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai...